3 unknown, 2 completed, 1 active not recruiting, 1 recruiting. 7 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 7 | Unknown 3, Completed 2, Active not recruiting 1, Recruiting 1 |
Follow Fasting: new trials by email Literature Review of Fasting trials Research Report on Fasting
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimization of Basal Insulin During Ramadan Fasting in Type 2 Diabetic Patients: Comparison Between DAR Recommendations and the Carbohydrate Fasting Test & Metabolic and Inflammatory Consequences Adjustment of insulin doses DAR, Adjustment of insulin doses CFT - Diabetes Mellitus, Type 2 Treated With Insulin, Fasting, Intermittent | Early Phase 1 | Active not recruiting | University Tunis El Manar | 100 | 2025-02-15 | 2026-09-10 |
| Time Restricted Eating in Sleep Apnea Time restricted eating - Time Restricted Eating, Obstructive Sleep Apnea | Early Phase 1 | Recruiting | University of California, San Diego | 80 | 2024-01-05 | 2024-01-16 |
| Pharmacokinetics of AUX-001 40mg Once-daily in Healthy Subjects Under Fasting and Fed Conditions AUX-001 40mg once-daily - Chronic Stable Angina | Early Phase 1 | Unknown | Auxilius Pharma sp.z.o.o. | 16 | 2023-11-27 | 2024-02-12 |
| The Role of Glucocorticoids to Maintain Energy Homeostasis During Starvation (Gluco-Starve) Metyrapone 250 mg Oral Tablets, Hydrocortisone 19.9mg s.c., pulsatile with a flow rate of 10μl/s, Placebo 250 mg Tablets - Glucocorticoid Effect | Early Phase 1 | Completed | Eleonora Seelig | 24 | 2023-05-15 | 2024-08-14 |
| Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®) - Healthy Volunteers, Fasting | Early Phase 1 | Completed | TAHO Pharmaceuticals Ltd. | 12 | 2022-12-05 | 2023-08-18 |
| BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma GC012F injection - Multiple Myeloma | Early Phase 1 | Unknown | Shanghai Changzheng Hospital | 15 | 2021-12-01 | 2021-09-22 |
| BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma GC012F injection - Multiple Myeloma | Early Phase 1 | Unknown | Shanghai Changzheng Hospital | 15 | 2020-01-16 | 2021-06-15 |
Intermittent Fasting (2) · Lecithin Cholesterol Acyltransferase Deficiency (2) · Multiple Myeloma (2) · Angina, Stable (1) · Diabetes Mellitus (1) · Hyperglycemia (1) · Hyperlipidemias (1) · Metabolic Syndrome (1) · Sleep Apnea Syndromes (1) · Sleep Apnea, Obstructive (1) · Starvation (1) · Weight Loss (1)
Behavior (7) · Feeding Behavior (7) · Nutritional and Metabolic Diseases (5) · Metabolic Diseases (4) · Cardiovascular Diseases (3) · Dyslipidemias (3) · Lipid Metabolism Disorders (3) · Vascular Diseases (3) · Blood Protein Disorders (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Glucose Metabolism Disorders (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2)
Hydrocortisone (1) · Metyrapone (1) · Tablets (1) · apixaban (1)
Shanghai Changzheng Hospital (2) · Auxilius Pharma sp.z.o.o. (1) · Eleonora Seelig (1) · TAHO Pharmaceuticals Ltd. (1) · University Tunis El Manar (1) · University of California, San Diego (1)
China (2) · United States (2) · Portugal (1) · Switzerland (1) · Tunisia (1)
Marlene Fonseca, MD (1) · Omar Mesarwi, MD (1) · Philip Mathew, M.D. (1)
2023 (1)